Oryzon Secures U.S. Patent for Iadademstat–Venetoclax Combination Therapies In Acute Myeloid Leukaemia, Strengthening Global Oncology IP

Oryzon Genomics has received a new U.S. patent from the United States Patent and Trademark Office covering therapeutic combinations involving iadademstat, its selective LSD1 inhibitor in clinical development for oncology and hematologic cancers. The patent protects treatment methods for neoplastic diseases, particularly acute myeloid leukaemia (AML), using iadademstat in combination with other anti-cancer agents.

Key claims include combination regimens pairing iadademstat with venetoclax, an established backbone therapy widely used in first-line AML treatment. The protection strengthens Oryzon’s intellectual property portfolio for combination strategies aimed at enhancing treatment effectiveness in aggressive blood cancers.

“This U.S. patent grant represents a significant addition to our growing IP portfolio for iadademstat,” said Neus Virgili, Oryzon’s Chief IP Officer. “This patent covers combinations with venetoclax, the current standard of care in first-line AML, and provides protection extending into 2039, strengthening the long-term value of our clinical programs.”

The patent is set to remain in force until January 2039, incorporating 681 days of patent term adjustment granted to offset regulatory review delays. Any additional patent term extensions linked to future regulatory approvals could further lengthen exclusivity. Iadademstat is currently under evaluation in 7 active oncology trials, including the Phase Ib ALICE-2 study testing the drug in combination with venetoclax and azacitidine in newly diagnosed AML patients.

Encouraging interim results from ALICE-2 were presented at the American Society of Haematology 2025 Annual Meeting, showing a 100% overall response rate and a 90% strict complete remission rate. The study continues to enrol patients rapidly, with updated findings expected at the European Haematology Association Annual Congress in June 2026. Beyond the U.S., Oryzon has secured patents for iadademstat combinations with venetoclax across multiple global markets and holds additional granted patents covering pairings with other AML therapies such as azacitidine and decitabine.